Abstract:Abstract Background Recent single-cell transcriptomic studies report that IDH-mutant gliomas share a common hierarchy of cellular phenotypes, independent of genetic subtype. However, the genetic differences between IDH-mutant glioma subtypes are prognostic, predictive of response to chemotherapy, and correlate with distinct tumor microenvironments. Results To reconcile these findings, we profile 22 human IDH-mutant gliomas using scATAC-seq and scRNA-seq. We determine the cell-type-specific differences in transcription factor expression and associated regulatory grammars between IDH-mutant glioma subtypes. We find that while IDH-mutant gliomas do share a common distribution of cell types, there are significant differences in the expression and targeting of transcription factors that regulate glial identity and cytokine elaboration. We knock out the chromatin remodeler ATRX, which suffers loss-of-function alterations in most IDH-mutant astrocytomas, in an IDH-mutant immunocompetent intracranial murine model. We find that both human ATRX-mutant gliomas and murine ATRX-knockout gliomas are more heavily infiltrated by immunosuppressive monocytic-lineage cells derived from circulation than ATRX-intact gliomas, in an IDH-mutant background. ATRX knockout in murine glioma recapitulates gene expression and open chromatin signatures that are specific to human ATRX-mutant astrocytomas, including drivers of astrocytic lineage and immune-cell chemotaxis. Through single-cell cleavage under targets and tagmentation assays and meta-analysis of public data, we show that ATRX loss leads to a global depletion in CCCTC-binding factor association with DNA, gene dysregulation along associated chromatin loops, and protection from therapy-induced senescence. Conclusions These studies explain how IDH-mutant gliomas from different subtypes maintain distinct phenotypes and tumor microenvironments despite a common lineage hierarchy.

Genetic Inactivation of ATRX Leads to a Decrease in the Amount of Telomeric Cohesin and Level of Telomere Transcription in Human Glioma Cells

ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner

Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX

ATRX Tolerates Activity-Dependent Histone H3 Methyl/phos Switching to Maintain Repetitive Element Silencing in Neurons.

Phosphorylation of 'SDT-like' motifs in ATRX mediates its interaction with the MRN complex and is important for ALT pathway suppression

Argininosuccinate Lyase Drives Activation of Mutant TERT Promoter in Glioblastomas

Functional Loss of ATRX and TERC Activates Alternative Lengthening of Telomeres (ALT) in LAPC4 Prostate Cancer Cells

The Chromatin Remodeler ATRX: Role and Mechanism in Biology and Cancer

Atrx Deficiency Induces Telomere Dysfunction, Endocrine Defects, and Reduced Life Span.

ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma

ATRX Loss Promotes Tumor Growth and Impairs Nonhomologous End Joining DNA Repair in Glioma

Loss of ATRX, Genome Instability, and an Altered DNA Damage Response Are Hallmarks of the Alternative Lengthening of Telomeres Pathway

Effects of p53 and ATRX inhibition on telomeric recombination in aging fibroblasts

ATRX Promotes Gene Expression by Facilitating Transcriptional Elongation Through Guanine-Rich Coding Regions.

Role of ATRX in chromatin structure and function: implications for chromosome instability and human disease

Cancer-associated DAXX mutations reveal a critical role for ATRX localization in ALT suppression

ATRX/DAXX: Guarding the Genome Against the Hazards of ALT

Switch Telomerase to ALT Mechanism by Inducing Telomeric DNA Damages and Dysfunction of ATRX and DAXX.

Alternative Lengthening of Telomeres Phenotype and Loss of ATRX Expression in Sarcomas.

Non‐telomerase telomere maintenance in human cells (97.2)

Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas